Assertio Holdings (NASDAQ:ASRT) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$29.2m (down 18% from 3Q 2023).
- Net loss: US$2.92m (loss narrowed by 99% from 3Q 2023).
- US$0.031 loss per share (improved from US$3.42 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Assertio Holdings Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 35%.
Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 16% from a week ago.
Risk Analysis
Be aware that Assertio Holdings is showing 1 warning sign in our investment analysis that you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:ASRT
Assertio Holdings
A commercial pharmaceutical company, provides various products to patients in the United States.
Very undervalued with flawless balance sheet.
